Drug · DIN 02557525
ZEPBOUND
MULTIDOSE PREFILLED PEN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 19, 2026; first marketed July 9, 2025.
- Drug Identification Number (DIN)
- 02557525
- Company (DIN owner)
- Eli Lilly Canada IncToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Tirzepatide A10BX16
- Class
- Human
- Record last updated
- September 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| TIRZEPATIDE | 7.5 MG | 0.6 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 12, 2026: NOC 36897Supplement to a New Drug Submission (SNDS) · Change in product name. Product Monograph reformatted to the Master Template. Update to Instructions for Use. New package labels. Update to package insert
- May 13, 2025: NOC 35344New Drug Submission (NDS)
Other DINs named ZEPBOUND
- DIN 02557509 · Marketed
- DIN 02557517 · Marketed
- DIN 02557533 · Marketed
- DIN 02557541 · Marketed
- DIN 02557568 · Marketed